BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 28873029)

  • 1. CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine?
    de Andrés F; Sosa-Macías M; Ramos BPL; Naranjo MG; LLerena A
    OMICS; 2017 Sep; 21(9):509-519. PubMed ID: 28873029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. To Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotype-Phenotype Concordance and Discordance in the Ecuadorian Population.
    De Andrés F; Terán S; Hernández F; Terán E; LLerena A
    OMICS; 2016 Dec; 20(12):699-710. PubMed ID: 27849442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
    Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
    OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
    Bosilkovska M; Samer C; Déglon J; Thomas A; Walder B; Desmeules J; Daali Y
    Basic Clin Pharmacol Toxicol; 2016 Sep; 119(3):284-90. PubMed ID: 27009433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population.
    de Andrés F; Altamirano-Tinoco C; Ramírez-Roa R; Montes-Mondragón CF; Dorado P; Peñas-Lledó EM; LLerena A
    Pharmacogenomics J; 2021 Apr; 21(2):140-151. PubMed ID: 33024249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.
    Skadrić I; Stojković O
    Int J Legal Med; 2020 Mar; 134(2):433-439. PubMed ID: 31858263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population.
    Céspedes-Garro C; Rodrigues-Soares F; Jiménez-Arce G; Naranjo MG; Tarazona-Santos E; Fariñas H; Barrantes R; Llerena A;
    Rev Biol Trop; 2016 Sep; 64(3):1067-76. PubMed ID: 29461783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P-Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What?
    Gazzaz M; Kinzig M; Schaeffeler E; Jübner M; Hsin CH; Li X; Taubert M; Trueck C; Iltgen-Breburda J; Kraus D; Queckenberg C; Stoffel M; Schwab M; Sörgel F; Fuhr U
    Clin Pharmacol Ther; 2018 Dec; 104(6):1249-1259. PubMed ID: 29633238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism.
    Dorado P; González I; Naranjo ME; de Andrés F; Peñas-Lledó EM; Calzadilla LR; LLerena A
    OMICS; 2017 Jan; 21(1):17-26. PubMed ID: 28271978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term fasting alters cytochrome P450-mediated drug metabolism in humans.
    Lammers LA; Achterbergh R; de Vries EM; van Nierop FS; Klümpen HJ; Soeters MR; Boelen A; Romijn JA; Mathôt RA
    Drug Metab Dispos; 2015 Jun; 43(6):819-28. PubMed ID: 25795462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
    Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
    Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population.
    Ota T; Kamada Y; Hayashida M; Iwao-Koizumi K; Murata S; Kinoshita K
    Int J Med Sci; 2015; 12(1):78-82. PubMed ID: 25552922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
    Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
    Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
    Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
    Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations.
    Zuo J; Xia D; Jia L; Guo T
    Pharmazie; 2012 Jul; 67(7):639-44. PubMed ID: 22888523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.
    Chamboko CR; Veldman W; Tata RB; Schoeberl B; Tastan Bishop Ö
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?
    Tanaka E; Kurata N; Yasuhara H
    J Clin Pharm Ther; 2003 Jun; 28(3):157-65. PubMed ID: 12795773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
    Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
    J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiplex Phenotyping for Systems Medicine: A One-Point Optimized Practical Sampling Strategy for Simultaneous Estimation of CYP1A2, CYP2C9, CYP2C19, and CYP2D6 Activities Using a Cocktail Approach.
    de Andrés F; Terán S; Bovera M; Fariñas H; Terán E; LLerena A
    OMICS; 2016 Feb; 20(2):88-96. PubMed ID: 26600202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
    Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
    Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.